Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
According to Celgene “pricing decisions reflect the benefits that our innovative therapies provide to patients, the healthcare system and society.” Let me translate this statement. Multiple myeloma patients have little choice because conventional oncology prescribes multiple myeloma patients to undergo specific chemotherapies such as Revlimid regardless of the cost, efficacy or side effects.
Further, revlimid is one of the most expensive chemotherapy drugs that MM patients and survivors will pay for.
Please consider evidence-based nutrition, supplementation and lifestyle integrative therapies shown to reduce toxicity while increasing the efficacy of chemotherapy regimens such as Revlimid (bortezomib).
If you increase the efficacy of revlimid (lenalidomide), you can reduce the dose of this expensive, toxic chemotherapy regimen. If you reduce your dose, you will not use as much of the drug…
I am both a long-term MM survivor and MM cancer coach. To learn more about managing your MM both conventionally and non-conventionally, please click the button below to sign up for a FREE webinar about Multiple Myeloma treatment options:
Have you been diagnosed with multiple myeloma? To learn more about integrative and complementary MM therapies to enhance the efficacy of revlimid while reducing your risks of side effects, scroll down the page, post a question or comment and I will reply to you ASAP.
“Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model. Its effect on the other IMid, lenalidomide, has not been evaluated. This study aims to investigate the mechanism of action of curcumin and its potential ability to positively interact with lenalidomide.
Method: we designed an in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in combination with lenalidomide on the human myeloma H929 cell line.
Results: Incubation of H929 cells with curcumin (30mM) or lenalidomide (2.5 mM) for 3 days resulted in 26.35% (±1.06) and 30.81%(±2.98) apoptotic cells respectively. When 30 mM curcumin was combined with 2.5 mM lenalidomide, 50.4% (±3.37) apoptotic cells were detected by flow cytometry and the increase was significant compared to either curcumin alone or lenalidomide alone (anova p = 0.0026). Furthermore, gene analysis studies show that curcumin enhances the cytotoxic effect of lenalidomide via suppression of the cereblon and multi-drug resistant genes.
Conclusion: Curcumin exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.”
“So far this year, Celgene has raised the price of Revlimid three times, taking the drug’s list price up 19.8% year to date, according to a note from SunTrust analyst Yatin Suneja. The drugmaker hauled in nearly $7 billion around the world last year with the med that treats multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes…
The company has also raised prices on Pomalyst twice so far in 2017, amounting to a 17.7% jump year to date, Suneja wrote. The multiple myeloma drug brought in $1.3 billion last year…
But the moves come during a tough period for pharma’s reputation, during which lawmakers and the U.S. public have blasted the industry’s pricing and pushed for regulatory reform. Instead, no action has happened on the national level, and some states are taking the issue into their own hands…
In a statement, a Celgene spokesperson said the company’s “pricing decisions reflect the benefits that our innovative therapies provide to patients, the healthcare system and society.” Celgene says the value of its drugs “continue to increase, supported by the growing clinical and real-world outcomes for patients in the approved indications.””